TuHURA Biosciences Inc. has announced that research on targeting the Delta Opioid Receptor (DOR) to reprogram myeloid-derived suppressor cells (MDSCs) has been accepted for oral presentation at the 67th American Society of Hematology $(ASH)$ Annual Meeting and Exposition, scheduled for December 6-9, 2025, in Orlando, Florida. The presentation will highlight findings demonstrating DOR expression on tumor-associated MDSCs and tumor-associated macrophages (TAMs), as well as the impact of DOR inhibition on their immunosuppressive functions. These results represent the first demonstration of DOR's role in these immune cells within the tumor microenvironment. Additional data, including a poster on the pathogenic role of DOR-expressing MDSCs in myelodysplastic syndrome (MDS), will also be presented at the meeting.